- Home
- IRON vs CENTA Comparison
IRON vs CENTA Comparison
Compare IRON & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- CENTA
- Stock Information
- Founded
- IRON 2017
- CENTA 1955
- Country
- IRON United States
- CENTA United States
- Employees
- IRON N/A
- CENTA N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- CENTA Consumer Specialties
- Sector
- IRON Health Care
- CENTA Consumer Discretionary
- Exchange
- IRON Nasdaq
- CENTA Nasdaq
- Market Cap
- IRON 2.1B
- CENTA 1.9B
- IPO Year
- IRON N/A
- CENTA 1993
- Fundamental
- Price
- IRON $59.76
- CENTA $35.52
- Analyst Decision
- IRON Strong Buy
- CENTA Buy
- Analyst Count
- IRON 12
- CENTA 4
- Target Price
- IRON $92.08
- CENTA $37.00
- AVG Volume (30 Days)
- IRON 330.3K
- CENTA 394.1K
- Earning Date
- IRON 08-11-2025
- CENTA 08-06-2025
- Dividend Yield
- IRON N/A
- CENTA N/A
- EPS Growth
- IRON N/A
- CENTA N/A
- EPS
- IRON N/A
- CENTA 1.87
- Revenue
- IRON N/A
- CENTA $3,155,810,000.00
- Revenue This Year
- IRON N/A
- CENTA $0.30
- Revenue Next Year
- IRON N/A
- CENTA $1.78
- P/E Ratio
- IRON N/A
- CENTA $18.68
- Revenue Growth
- IRON N/A
- CENTA N/A
- 52 Week Low
- IRON $30.82
- CENTA $27.70
- 52 Week High
- IRON $68.73
- CENTA $37.35
- Technical
- Relative Strength Index (RSI)
- IRON 61.73
- CENTA 57.29
- Support Level
- IRON $58.63
- CENTA $35.78
- Resistance Level
- IRON $61.59
- CENTA $37.35
- Average True Range (ATR)
- IRON 2.15
- CENTA 0.88
- MACD
- IRON -0.14
- CENTA -0.16
- Stochastic Oscillator
- IRON 64.07
- CENTA 23.85
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About CENTA Central Garden & Pet Company Nonvoting
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.